Poor
Partially Aligned
Patient Risk:
Low
Summary
The response discusses many interaction and toxicity details, but the provided label excerpts do not support specific claims about those interactions (e.g., NSAIDs, trimethoprim/sulfonamides, warfarin, PPIs, probenecid, PPIs, acid-reducers) or most specific “signs” of toxicity. Only the embryo-fetal toxicity, hypersensitivity/anaphylaxis discontinuation, and general severe adverse reaction/discontinuation concepts are clearly supported by the supplied JYLAMVO prescribing information excerpts.
Category Scores
Accurate Statements
JYLAMVO/methotrexate can cause severe adverse reactions and may require withholding or discontinuation in severe toxicity contexts (e.g., life-threatening complications).
2.6 (dosage modifications for adverse reactions: discontinue/withhold for multiple severe toxicities such as myelosuppression, severe GI toxicity, hepatotoxicity, pulmonary toxicity, severe dermatologic reactions, severe renal toxicity, serious infections, neurotoxicity) and 5 (Warnings and Precautions for severe/fatal events).
Methotrexate suppresses hematopoiesis and can cause severe, life-threatening blood count suppression requiring monitoring (myelosuppression/pancytopenia).
5.3 Myelosuppression: severe and life-threatening pancytopenia and obtain blood counts baseline/periodically.
Methotrexate can cause embryo-fetal toxicity including fetal death; JYLAMVO is contraindicated in pregnant women for treatment of non-neoplastic diseases; advise contraception for females of reproductive potential during treatment and after final dose.
5.1 Embryo-Fetal Toxicity; 4 Contraindications; 8.1 Pregnancy; 8.3 Females and Males of Reproductive Potential.
Unsupported Statements
The most important methotrexate interaction risks involve kidney function, blood counts, and liver toxicity.
The provided label excerpts include general warnings about renal/hepatic toxicity and myelosuppression, and a general interaction principle that some coadministered products may increase methotrexate concentrations and severe adverse reactions; however, the response provides a prioritized list (“most important”) not directly supported by the supplied text.
Methotrexate interactions can involve additive blood-count effects with other drugs that suppress bone marrow or lower blood cells.
The provided label excerpts do not explicitly state additive blood-count effects with other bone-marrow-suppressing drugs.
Methotrexate may build up with drugs that stress the kidneys or compete for kidney clearance.
No specific statement in the supplied excerpts supports this mechanistic claim about competing for kidney clearance or accumulation with “kidney-stressing” drugs.
Methotrexate can have increased liver toxicity risk with drugs that increase liver toxicity.
While hepatotoxicity is warned, the provided excerpts do not support this specific interaction framing.
NSAIDs can raise the risk of methotrexate toxicity by reducing methotrexate clearance through the kidneys.
The provided excerpts mention aspirin/NSAIDs in the list of drug categories that may increase methotrexate plasma concentrations and severe adverse reactions, but do not support the specific mechanism (“reducing clearance through the kidneys”).
The risk of methotrexate toxicity from NSAIDs is higher with higher methotrexate doses, especially in oncology settings; with kidney disease or dehydration; with dehydrating illnesses such as vomiting or diarrhea; with long courses or higher NSAID doses.
These specific risk modifiers and clinical contexts are not supported by the supplied label excerpts.
Trimethoprim-containing antibiotics (e.g., trimethoprim-sulfamethoxazole) can increase the risk of low blood counts when used with methotrexate.
The provided excerpts do not specifically name trimethoprim-sulfamethoxazole or low blood counts risk from that combination.
The trimethoprim plus methotrexate combination can be especially risky for people with low blood counts or reduced kidney function.
Not supported by the supplied excerpts.
Some acid-reducing medicines have been associated with altered methotrexate clearance in certain cases, particularly in higher-dose regimens or with kidney impairment.
Although the interaction list excerpt mentions proton pump inhibitors, it does not provide the specific association language, risk modifiers, or scenarios described in the response.
Methotrexate can affect blood clotting control in some patients taking warfarin.
The provided label excerpts do not include warfarin-specific interaction information.
People taking anticoagulants generally need closer monitoring to ensure INR (for warfarin) and overall bleeding risk stay in range.
Warfarin/INR-specific monitoring is not supported by the supplied excerpts.
Some medications can change liver metabolism or kidney handling and thereby alter methotrexate levels or increase liver/blood side effects.
The label excerpt supports that some coadministration may increase methotrexate plasma concentrations and severe adverse reactions, but does not support the broad claim that medications change “liver metabolism or kidney handling” in the specific manner described.
Dangerous methotrexate toxicity can occur, especially soon after starting a new interacting medication.
The label excerpt does not state timing relative to start of interacting medications.
Signs of methotrexate toxicity include mouth sores, sore throat, or unusual ulcers.
The provided excerpts include ulcerative stomatitis as a common adverse reaction in clinical trials, but do not support a broader set of “signs” or the specific inclusion of “sore throat” or “unusual ulcers” as labeled toxicity signs.
Signs of methotrexate toxicity include unusual bruising, bleeding, or severe fatigue, which may indicate low blood counts.
The label excerpt discusses myelosuppression and need to monitor for clinical complications, but does not provide these specific symptom-to-lab interpretations as listed “signs.”
Signs of methotrexate toxicity include fever or infections that seem out of proportion.
The label warns to report new onset fever and symptoms of infection, but does not support the additional phrase “seem out of proportion.”
Signs of methotrexate toxicity include shortness of breath and persistent nausea or vomiting.
Shortness of breath could relate to pulmonary toxicity, but the supplied excerpts do not list these specific symptoms as “signs of methotrexate toxicity.” Persistent nausea/vomiting is mentioned generally under GI toxicity categories, but not as a labeled “signs” list for toxicity in the way stated.
Signs of methotrexate toxicity include yellowing of the skin/eyes or dark urine, which may indicate liver injury.
The supplied excerpts do not list these specific symptom descriptions for hepatotoxicity.
Signs of methotrexate toxicity include decreased urination or swelling, which may indicate kidney stress.
The supplied excerpts do not list these specific symptom descriptions for renal toxicity.
Methotrexate interaction risk rises with kidney impairment or dehydration; with liver disease or heavy alcohol use; with blood disorders or low baseline blood counts; with higher methotrexate doses; with recent start or stop of another interacting medication.
The provided excerpts support that renal/hepatic toxicity and myelosuppression can be severe and require monitoring, but do not support these specific “risk rises” assertions or the detailed modifiers (heavy alcohol use; timing with start/stop of interacting medication) as written.
Contradictions
Important Omissions
No explicit discussion of pregnancy contraindication details are included in the provided interaction/signs list (contraception timing, contraindication only for non-neoplastic diseases, and counseling specifics).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Because most interaction specifics and symptom lists are not supported by the provided JYLAMVO prescribing information excerpts, the response could mislead about interaction risks and toxicity indicators. However, it does not directly contradict contraindications or core severe-toxicity warnings present in the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Major portions of the response contain interaction-specific claims and symptom “signs” not supported by the supplied label excerpts (e.g., NSAID mechanisms and risk modifiers, trimethoprim-sulfamethoxazole specifics, warfarin/INR statements, and detailed symptom lists).
Suggested Improvement
Restrict interaction and symptom statements to what is explicitly supported in the provided excerpts (general warning that coadministration may increase methotrexate concentrations and severe adverse reactions; specific labeled severe toxicity categories; and label-consistent examples like ulcerative stomatitis and the presence of myelosuppression/serious infections counseling), and remove unsupported mechanistic/risk-modifier and drug-specific claims not contained in the provided text.